Morepen Laboratories Limited share price
NSE: MOREPENLAB · ISIN INE083A01026
Key numbers
- Market cap
- ₹ 6,596 Cr
- Current price
- ₹ 120.38
- 52-week high / low
- ₹ 127 / 33
- Stock P/E
- 46.8
- Book value
- ₹ 22.2
- Dividend yield
- 0.17%
- ROCE
- 10.0%
- ROE
- 7.9%
- Debt to equity
- 0.17
- Sales growth (3 yrs)
- 8.4%
- Profit growth (3 yrs)
- 34.9%
- 1-year return
- 136.9%
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 425 | 412 | 484 | 485 | 570 |
| Operating profit | 24 | 31 | 46 | 24 | 83 |
| Net profit | 11 | 41 | 28 | 16 | 56 |
| EPS (₹) | 0.20 | 0.75 | 0.50 | 0.28 | 1.03 |
Investor presentation summary (2026-08-04)
AI summary of the presentation · tone: Positive · source document
Key numbers
- RevenueRevenue Revenue +34%+34%+34%
Guidance & outlook
- Q1'FY27 Investor PresentationQ1'FY27 Investor PresentationQ1'FY27 Investor Presentation
- Q1 FY27 — A Quarter of Commercial ValidationQ1 FY27 — A Quarter of Commercial ValidationQ1 FY27 — A Quarter of Commercial Validation
Growth & demand
- 31% API Growth31% API Growth31% API Growth API Export Up 42%API Export Up 42%API Export Up 42%
- Core API franchise stabilising while CDMO becomes the next growth layer.Core API franchise stabilising while CDMO becomes the next growth layer.Core API franchise stabilising while CDMO becomes the next growth layer.
Margins & costs
- Higher marginsHigher margins
- EBITDA MarginEBITDA MarginEBITDA Margin
Capex & expansion
- Capacity RealignmentCapacity RealignmentCapacity Realignment
- Capacity AugmentationCapacity AugmentationCapacity Augmentation Global PartnershipsGlobal PartnershipsGlobal Partnerships
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.